about
Veterinary homeopathy: systematic review of medical conditions studied by randomised trials controlled by other than placeboAn optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Validation of a multiprotein plasma classifier to identify benign lung nodulesGeneral guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.The role of adaptive trial designs in drug development.On generalized fixed sequence procedures for controlling the FWER.Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials.Mixture-based gatekeeping procedures in adaptive clinical trials.Type-II generalized family-wise error rate formulas with application to sample size determination.Advances in p-Value Based Multiple Test Procedures.Consistency ensured test strategies for supportive evidence of treatment efficacy in noninferiority clinical trials.Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.Composite and multicomponent end points in clinical trials.Some remaining challenges regarding multiple endpoints in clinical trials.Editorial: Multiplicity issues in clinical trials.Multiplicity considerations in subgroup analysis.An enhanced mixture method for constructing gatekeeping procedures in clinical trials.Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.Non-factorial analyses of two-by-two factorial trial designs.Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypotheses.Traditional multiplicity adjustment methods in clinical trials.Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
P2860
Q26786899-A1D09A1F-96B6-46EB-BAFD-7F25D45D11C7Q33569474-D4424FED-5F8E-4211-AF82-DFFE7051B087Q35241794-1011A1E6-B21E-47C5-9D3B-D2ECAFB2D022Q38586261-A74E4215-A42A-4EB8-9572-97A9551B0063Q38590548-9F4FBED3-7F51-4611-9097-0DFDA186BF5DQ38691922-35848398-8506-4AD8-9818-529988375D7AQ40675906-C153A23B-845A-4D0B-B225-3C6AB232C690Q40796122-D14927B1-F6BE-43F2-B6B9-B42FA6E09721Q46360497-C2E70201-0FF4-40FD-AF69-25FF58C369D3Q47240098-662F7856-0DE2-404D-B5AA-A017FB9EF90FQ47322964-91D796EA-85B7-47BF-93D5-D34A05346CA8Q47408459-21C2A686-8A05-4B51-AA7B-C6143AF5B2D5Q47573172-8E769D3E-64CE-46D2-BE7B-0349CC5A8FB0Q47691559-1BB94AF2-00C0-467F-BD24-F35C6A39E476Q48179835-7C034092-443B-4BF4-BFE4-452D873C7A12Q48197136-AE67C514-A4CA-4D78-9234-5F0F9922907EQ48270494-3E6C3191-F695-4512-8E4B-B026C2DB727AQ48315216-42689278-47BE-4867-84CE-15D2852BE50CQ49846428-85F8AEB4-6CAD-46CF-849B-7F9BFA7601D2Q50070354-B25576DE-1520-4F32-8049-07441E8ED960Q50607045-75AF1D06-E777-4BB1-B0BF-B4DF950FF988Q50870862-6E9A2542-7DB7-4622-ACAE-54BA35F8CB44Q51152686-A4884CA1-60A9-48B1-8F67-0D0E5B908371Q52470298-6CF4B471-3396-477F-BE57-66421C52097F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Key multiplicity issues in clinical drug development.
@en
type
label
Key multiplicity issues in clinical drug development.
@en
prefLabel
Key multiplicity issues in clinical drug development.
@en
P2093
P2860
P356
P1476
Key multiplicity issues in clinical drug development.
@en
P2093
Alex Dmitrienko
Mohammad F Huque
Ralph B D'Agostino
P2860
P304
P356
10.1002/SIM.5642
P407
P577
2012-10-09T00:00:00Z